204 related articles for article (PubMed ID: 32096304)
1. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma.
Kondo S; Ota A; Ono T; Karnan S; Wahiduzzaman M; Hyodo T; Lutfur Rahman M; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
Cancer Med; 2020 Apr; 9(8):2904-2917. PubMed ID: 32096304
[TBL] [Abstract][Full Text] [Related]
2. High frequency of BRAF V600E mutations in ameloblastoma.
Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
[TBL] [Abstract][Full Text] [Related]
3. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract][Full Text] [Related]
4. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
5. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
6. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
7. Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway.
Nakao Y; Mitsuyasu T; Kawano S; Nakamura N; Kanda S; Nakamura S
Int J Oncol; 2013 Nov; 43(5):1377-84. PubMed ID: 24002438
[TBL] [Abstract][Full Text] [Related]
8. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical biomarkers in ameloblastomas.
do Canto AM; Rozatto JR; Schussel JL; de Freitas RR; Hasséus B; Braz-Silva PH
Acta Odontol Scand; 2016 Nov; 74(8):585-590. PubMed ID: 27571891
[TBL] [Abstract][Full Text] [Related]
10. Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature.
Davanian H; Balasiddaiah A; Heymann R; Sundström M; Redenström P; Silfverberg M; Brodin D; Sällberg M; Lindskog S; Kruger Weiner C; Chen M
Oncotarget; 2017 Jan; 8(3):4530-4542. PubMed ID: 27965463
[TBL] [Abstract][Full Text] [Related]
11. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor.
Krishna A; Kaveri H; Naveen Kumar RK; Kumaraswamy KL; Shylaja S; Murthy S
J Cancer Res Ther; 2012; 8(2):232-7. PubMed ID: 22842367
[TBL] [Abstract][Full Text] [Related]
13. Ameloblastoma-Clinical, radiological, and therapeutic findings.
Kreppel M; Zöller J
Oral Dis; 2018 Mar; 24(1-2):63-66. PubMed ID: 29480593
[TBL] [Abstract][Full Text] [Related]
14. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Periostin expression in the pathogenesis of ameloblastoma.
Kang Y; Liu J; Zhang Y; Sun Y; Wang J; Huang B; Zhong M
Pathol Res Pract; 2018 Dec; 214(12):1959-1965. PubMed ID: 30196986
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of ameloblastoma.
Marín-Márquez C; Kirby J; Hunter KD
J Oral Pathol Med; 2024 May; 53(5):277-293. PubMed ID: 38664938
[TBL] [Abstract][Full Text] [Related]
17. The landscape of genetic alterations in ameloblastomas relates to clinical features.
Gültekin SE; Aziz R; Heydt C; Sengüven B; Zöller J; Safi AF; Kreppel M; Buettner R
Virchows Arch; 2018 May; 472(5):807-814. PubMed ID: 29388014
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity of the PTCH gene in ameloblastoma.
Farias LC; Gomes CC; Brito JA; Galvão CF; Diniz MG; de Castro WH; Bernardes Vde F; De Marco LA; Gomez RS
Hum Pathol; 2012 Aug; 43(8):1229-33. PubMed ID: 22221699
[TBL] [Abstract][Full Text] [Related]
19. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
20. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
